We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EGFR inhibitors square off at ASCO.
- Authors
Baker, Monya
- Abstract
Competition in the nascent targeted-cancer therapeutic market is expected to heat up at the annual meeting of the American Society of Clinical Oncologists held on June 5-8, where clinical researchers will reveal data from dozens of studies of five epidermal growth factor receptor (EGFR) inhibitors. By establishing themselves against different cancer types, the first two EGFR inhibitors to the market staked out different patients. How the market plays out will depend on which cancers are most responsive to EGFR inhibitors, and which patient subpopulations respond to which drugs.
- Subjects
THERAPEUTICS; ONCOLOGISTS; ASSOCIATIONS, institutions, etc.; CANCER education; MEDICAL research; EPIDERMAL growth factor
- Publication
Nature Biotechnology, 2004, Vol 22, Issue 6, p641
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0604-641